The infiltrative nature of the tumor makes it difficult for surgeons to achieve a negative surgical margin, leading to frequent recurrences in up to 35% of patients [5]. Estrogen and progesterone receptor-positive tumors can show treatment response to GnRH agonists both preoperatively and after recurrence [5,6]. This evidence concerns the gene PGR and neoplasm.